Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)

Market Cap	57.58B +404.0%
Revenue (ttm)	1.96B +42.7%
Net Income	422.88M +177.0%
EPS	0.99 +171.8%
Shares Out	446.90M
PE Ratio	70.58
Forward PE	69.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,161,363
Open	65.40
Previous Close	64.70
Day's Range	65.25 - 70.75
52-Week Range	21.54 - 75.30
Beta	0.14
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About HKG:2315

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 1,922
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2315

Financial Performance

In 2025, HKG:2315's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 30, 2026

Data Sources Report a data error